// App-Quantinova.ai

560 : Addition of pazopanib (PZ) to endocrine therapy in hormone resistant advanced breast cancer (ABC).

Researchers

Presenter

  • Melanie Catherine Majure

Principal Investigators

  • Ariadna Gasol Cudos

  • Austin Nicholas Angelidakis

  • Michelle E. Melisko

  • Ariel R. Karwat

  • Amy Jo Chien

  • Andrei Goga

  • Mark M. Moasser

  • John W. Park

  • Amy N. DeLuca

  • Hope S. Rugo

Medical Centers

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • Hospital Universitari Arnau de Vilanova, Lleida, Spain

  • University of California, San Francisco, San Francisco, CA

  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • UC San Francisco, San Francisco, CA

Locations

  • United States

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Anastrozole

  • Letrozole

  • Pazopanib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01466972

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved